Long-term Investigation of Resveratrol in Obesity — LIRMOI  

Obesity Clinical Trial

Official title: Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds

Status Completed

Clinical Trial Summary

The aim of this study is to investigate potential metabolic effects of resveratrol in men with metabolic syndrome(otherwise healthy).

The investigators hypothesize that resveratrol has an anti-inflammatory effect, and will increase insulin sensitivity, change the fat- and sugar-metabolism, and down-regulate bone-turnover.

Clinical Trial Description

The study will be done in a collaboration between two PhD students, who focus on effects in adipose- and muscle- tissue, and bone tissue respectively.

The investigators will look at changes in

• inflammation-markers

• biochemical markers of fat- and sugar-metabolism

• gene-expression in fat- and muscle-tissue

• body composition (DXA (whole body) and MR spectroscopy)

• biochemical markers of bone-metabolism

• Bone Mineral Density (DXA scans)

• bone structure (QCT)

• gene-expression and cytokines in bone marrow

Some of the volunteers will have their insulin sensitivity measured. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Inflammation
• Insulin Resistance
• Insulin Sensitivity
• Obesity
• Osteoporosis

• NCT number: NCT01412645
• Study type: Interventional
• Source: University of Aarhus
• Status: Completed
• Phase: N/A
• Start date: August 2011
• Completion date: August 2013